Supportive Care in Advanced Lung Cancer Patients
Author Information
Author(s): Di Maio M, Perrone F, Gallo C, Iaffaioli R V, Manzione L, Piantedosi F V, Cigolari S, Illiano A, Barbera S, Robbiati S F, Piazza E, Ianniello G P, Frontini L, Veltri E, Castiglione F, Rosetti F, De Maio E, Maione P, Gridelli C
Primary Institution: National Cancer Institute, Naples, Italy
Hypothesis
What is the impact of chemotherapy and patient characteristics on the use of supportive care drugs in patients with advanced non-small-cell lung cancer?
Conclusion
Patients with advanced non-small-cell lung cancer often require multiple supportive care drugs alongside chemotherapy, which can lead to compliance and safety issues.
Supporting Evidence
- Patients assumed an average of 2.43 supportive drugs during chemotherapy.
- 75.8% of patients took at least one supportive drug.
- Chemotherapy type influenced the number of supportive drugs used.
Takeaway
Patients with lung cancer often take many different medicines to help with side effects and other problems, which can be confusing and risky.
Methodology
Data were collected from three randomized clinical trials involving patients with advanced NSCLC, focusing on the number and types of supportive drugs used during chemotherapy.
Potential Biases
Potential biases may arise from differences in patient characteristics and treatment protocols across the trials.
Limitations
The study is a secondary analysis of three trials, which may introduce biases and limit the generalizability of the findings.
Participant Demographics
The median age of participants was 74 years, with a majority being male (84%).
Statistical Information
P-Value
0.22
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website